Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
Melbourne (Australia) and Indianapolis (United States) | 28 February 2026
PROMISE (PROstate cancer Molecular Imaging Standardized Evaluation)-PET is a multi-center, prospective, observational, non-interventional registry study designed to enable research assessing the prognostic value of PSMA-PET and comparing it with established clinical risk scores in early and late stages of disease. The registry has been collecting and analyzing patient data since 2018 and, to date, PET readings from more than 15,000 patients across over 50 institutions globally have been standardized using the PROMISE framework, with PSMA-PET and PROMISE confirmed as a novel prognostic biomarker for prostate cancer using both internal and external validation cohorts[3].
The aim of this new collaboration with Telix is to develop and validate AI-based prediction models for survival, leveraging gallium-68 (68Ga)-PSMA-11-PET imaging data, using the automated machine learning (“AutoML”) engine that powers Telix’s AI platform[4], and comparing performance with established clinically prognostic nomograms. PSMA-PET imaging represents a significant advance in prostate cancer management and is now considered standard of care, offering greater accuracy than conventional imaging (computed tomography and bone scans) after initial diagnosis and for detecting recurrence[5]. However, there remains an opportunity to better understand whether PSMA-PET imaging data can be correlated to patient outcomes.
Wolfgang Fendler, MD, Professor, Department of Nuclear Medicine, University Hospital Essen, commented, “We are pleased to welcome Telix – a leading global innovator in radiopharma – to the PROMISE-PET registry to support us in this important research in prostate cancer. Telix’s AI platform has the potential to build on existing results and leverage one of the world’s largest PSMA-PET datasets to support improved risk stratification and inform future guideline recommendations and clinical decision making.”
Simon Wail, Director of AI Research, Telix, added, “Joining the PROMISE-PET registry is an exciting moment for Telix. Working together with leading investigators and having access to global, longitudinal, standardized PSMA-PET data will enable us to build, test and validate clinically relevant prognostic models that we believe will help clinicians in their treatment and management of patients with prostate cancer.”
For further information on the PROMISE-PET registry, visit: https://www.promise-pet.org
[1] ClinicalTrials.gov ID: NCT06320223.
[2] Imaging of prostate-specific membrane antigen with positron emission tomography.
[3] Eiber et al. J Nucl Med. 2018 (PROMISE V1); Seifert et al. European Urology. 2023 (PROMISE V2).
[4] Telix ASX disclosure April 27, 2023.
[5] EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5; Fendler et al. EJNMMI. 2023.